Lichtlen reale (15 resultados)

hardback. 1991. Adalat A Comprehensive Review. There are many charts, tables and graphs. Nifedipine 237 Very good to fine in a very good dust wrapper.

Hardcover. Condición: Very Good. Estado de la sobrecubierta: Very Good. 0387540334. Blue cloth hardcover, from closed pharmaceutical company library, with usual labels, marks. Lending record shows this book has never been borrowed. 237 pages, index, illustrated with charts, tables and diagrams. This volume documents the Adalat story, from its beginnings in research and development to its pioneering role in new areas of pharmacological treatment. Adalat is effective in treating hypertension, acute neurology, dementia, atherosclerosis and heart failure. This book surveys a chapter in the history of cardiovascular research. Sections include: Adalat History; Hypertension; Coronory Heart Disease; Coronory Atherosclerosis; Outlook, Adalat: Its Future. Contents appears unread, clean, tight and bright. Book.…

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: New. In English.

Condición: New.

Condición: New. pp. 260.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.…

Paperback. Condición: Brand New. reprint edition. 252 pages. 9.25x6.10x0.62 inches. In Stock.

Hard Cover. Condición: Good. [Por]. (Eds.). Springer-Verlag. Berlin. 1991. De 24x16 cm. Com 237, [ii] págs. Encadernação do editor. Ilustrado no texto com gráficos, desenhos e fotografias a cores e a preto e branco. Language: Inglês / English Location/localizacao: SACO RS705-06.

Condición: new. Questo è un articolo print on demand.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge. 260 pp. Englisch.…

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 260 pp. Englisch.…

Condición: New. Print on Demand pp. 260 67 Figures.

Condición: New. PRINT ON DEMAND pp. 260.